711 related articles for article (PubMed ID: 31266904)
21. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
Wada M; Noda Y; Shinagawa S; Chung JK; Sawada K; Ogyu K; Tarumi R; Tsugawa S; Miyazaki T; Yamagata B; Graff-Guerrero A; Mimura M; Nakajima S;
J Alzheimers Dis; 2018; 63(2):861-869. PubMed ID: 29689728
[TBL] [Abstract][Full Text] [Related]
22. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
[TBL] [Abstract][Full Text] [Related]
23. Understanding the effect of cognitive/brain reserve and depression on regional atrophy in early Alzheimer's disease.
Capogna E; Manca R; De Marco M; Hall A; Soininen H; Venneri A
Postgrad Med; 2019 Sep; 131(7):533-538. PubMed ID: 31478419
[No Abstract] [Full Text] [Related]
24. Erlangen Score Predicts Cognitive and Neuroimaging Progression in Mild Cognitive Impairment Stage of Alzheimer's Disease.
Skillbäck T; Kornhuber J; Blennow K; Zetterberg H; Lewczuk P;
J Alzheimers Dis; 2019; 69(2):551-559. PubMed ID: 31104027
[TBL] [Abstract][Full Text] [Related]
25. Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease.
Dicks E; Vermunt L; van der Flier WM; Visser PJ; Barkhof F; Scheltens P; Tijms BM;
Neuroimage Clin; 2019; 22():101786. PubMed ID: 30921610
[TBL] [Abstract][Full Text] [Related]
26. Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms.
Brendel M; Sauerbeck J; Greven S; Kotz S; Scheiwein F; Blautzik J; Delker A; Pogarell O; Ishii K; Bartenstein P; Rominger A;
J Alzheimers Dis; 2018; 65(3):793-806. PubMed ID: 30010116
[TBL] [Abstract][Full Text] [Related]
27. Association of the Informant-Reported Memory Decline With Cognitive and Brain Deterioration Through the Alzheimer Clinical Continuum.
Kuhn E; Perrotin A; La Joie R; Touron E; Dautricourt S; Vanhoutte M; Vivien D; de La Sayette V; Chételat G;
Neurology; 2023 Jun; 100(24):e2454-e2465. PubMed ID: 37085328
[TBL] [Abstract][Full Text] [Related]
28. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
Podhorna J; Krahnke T; Shear M; Harrison JE;
Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
[TBL] [Abstract][Full Text] [Related]
29. Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid-β Positron Emission Tomography.
Beyer L; Brendel M; Scheiwein F; Sauerbeck J; Hosakawa C; Alberts I; Shi K; Bartenstein P; Ishii K; Seibyl J; Cumming P; Rominger A;
J Alzheimers Dis; 2020; 74(1):101-112. PubMed ID: 31985461
[TBL] [Abstract][Full Text] [Related]
30. Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects.
Araque Caballero MÁ; Klöppel S; Dichgans M; Ewers M;
J Alzheimers Dis; 2017; 55(1):343-358. PubMed ID: 27662291
[TBL] [Abstract][Full Text] [Related]
31. Apolipoprotein E allele 4 effects on Single-Subject Gray Matter Networks in Mild Cognitive Impairment.
Sanabria-Diaz G; Demonet JF; Rodriguez-Herreros B; Draganski B; Kherif F; Melie-Garcia L
Neuroimage Clin; 2021; 32():102799. PubMed ID: 34469849
[TBL] [Abstract][Full Text] [Related]
32. Alzheimer disease biomarkers are associated with body mass index.
Vidoni ED; Townley RA; Honea RA; Burns JM;
Neurology; 2011 Nov; 77(21):1913-20. PubMed ID: 22105948
[TBL] [Abstract][Full Text] [Related]
33. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
[TBL] [Abstract][Full Text] [Related]
34.
Mirza SS; Saeed U; Knight J; Ramirez J; Stuss DT; Keith J; Nestor SM; Yu D; Swardfager W; Rogaeva E; St George Hyslop P; Black SE; Masellis M;
Neurology; 2019 Nov; 93(19):e1807-e1819. PubMed ID: 31575706
[TBL] [Abstract][Full Text] [Related]
35. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study.
Goukasian N; Hwang KS; Romero T; Grotts J; Do TM; Groh JR; Bateman DR; Apostolova LG
BMJ Open; 2019 Dec; 9(12):e031947. PubMed ID: 31857304
[TBL] [Abstract][Full Text] [Related]
36. Impact of Resilience on the Association Between Amyloid-β and Longitudinal Cognitive Decline in Cognitively Healthy Older Adults.
Wolf D; Fischer FU; Fellgiebel A;
J Alzheimers Dis; 2019; 70(2):361-370. PubMed ID: 31256140
[TBL] [Abstract][Full Text] [Related]
37. Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region.
Chen K; Roontiva A; Thiyyagura P; Lee W; Liu X; Ayutyanont N; Protas H; Luo JL; Bauer R; Reschke C; Bandy D; Koeppe RA; Fleisher AS; Caselli RJ; Landau S; Jagust WJ; Weiner MW; Reiman EM;
J Nucl Med; 2015 Apr; 56(4):560-6. PubMed ID: 25745091
[TBL] [Abstract][Full Text] [Related]
38. White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-β.
Freeze WM; Jacobs HI; Gronenschild EH; Jansen JF; Burgmans S; Aalten P; Clerx L; Vos SJ; van Buchem MA; Barkhof F; van der Flier WM; Verbeek MM; Rikkert MO; Backes WH; Verhey FR;
J Alzheimers Dis; 2017; 55(1):333-342. PubMed ID: 27662299
[TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
[TBL] [Abstract][Full Text] [Related]
40. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
